Trials / Terminated
TerminatedNCT02284971
Pilot Study of SBRT and CDX-1127 in Prostate Cancer
A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- James Larner, MD · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the combination of stereotactic body radiation therapy (SBRT) and CDX-1127 in subjects with castration resistant prostate cancer. Subjects will be randomized to one of three arms to receive SBRT prior to, after, or in conjunction with the first dose of CDX-1127.
Detailed description
This pilot study will be conducted in subjects with metastatic prostate cancer in order to define whether inclusion of immune regulation agents such as CDX-1127 augments immune responses to SBRT-treated primary tumors or metastases, and whether inclusion of CDX-1127 in the treatment regimen results in immune responses in untreated metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CDX1127 | |
| RADIATION | SBRT |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-04-07
- Completion
- 2016-04-07
- First posted
- 2014-11-06
- Last updated
- 2018-05-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02284971. Inclusion in this directory is not an endorsement.